Q3 2020 Sales Performance
•
Dostarlimab (PD-1 antagonist)
•
Endometrial cancer is the most common gynecological cancer in the US
GARNET is the largest study of anti-PD-1 monotherapy in patients with recurrent or
advanced endometrial cancer
Data at SGO 2020 in patients with recurrent or advanced dMMR endometrial cancer
Overall response rate (ORR) of 42% and disease control rate (DCR) 58%, by RECIST v1.1*
Development strategy for use in:
2/3L
treatment in patients
with advanced solid
tumors (GARNET)
1L
Treatment (RUBY)
Study start Read-out
monotherapy
dMMR/MSI-H EC
pivotal
2017
2H19
BLA accepted,
n=75
Presented at SGO 2020
dMMR/MSI-H tumor
agnostic
monotherapy
pivotal
2018
2H20
n=50
MMRP/MSS EC
pivotal
monotherapy
n=100
2017
2H19
Endometrial cancer
pivotal
dMMR/MSI-H and
MMRP/MSS patients
combo w chemo
n=470
2H 2019
2021
As determined by NGS test
** Based on pooled data from studies that used either 200 mg every 3 weeks or 10 mg/kg every 2 weeks
gsk
55
59View entire presentation